



BRIGHAM AND
WOMEN'S HOSPITAL



Sex and Gender in Cardiovascular Disease

Congressional Briefing

March 28, 2007


Paula A. Johnson, MD, MPH

**Chief, Division of Women's Health
Executive Director, Connors Center for Women's
Health and Gender Biology**



HARVARD
MEDICAL SCHOOL
TEACHING AFFILIATE


Leading causes of death among women



Source: CDC, Office of Women's Health, Leading Causes of Death, Females, US 2003


More Women Die from Heart Disease Than Men

Heart Disease Mortality in Women and Men Absolute Number of Deaths, 1979-2004



Source: American Heart Association. Heart Disease and Stroke Statistics–2007 Update.


Mortality Rate For U.S. Women By Race/Ethnicity, 2002



Cardiovascular Disease in Women

- Heart disease claims the lives of more women than the next five causes of death *combined*
- Only 21% of US women believe that heart disease and stroke are their greatest health threats
(26% white, 15% black, 7% Hispanic)
- Women are, on average, ten years older than men at the time of their first heart attack and are more likely to die
- 64% of women vs. 50% of men who died suddenly of CHD had no previous symptoms


Frequency of Presenting Symptoms other than Chest Pain in Acute MI




Source: Milner et. al *AM J Cardiol.* 1999; 84:396-399

Cardiovascular Disease can be Different in Women

**Blockage in male
coronary artery**



**Blockage in female
coronary artery**




Gould. *Coronary Artery Stenosis and Reversing Atherosclerosis*, 2nd ed. 1999.


Sex Differences in Physiology in Myocardial Infarction



Plaque Rupture



Plaque Erosion



More commonly seen in women

Secondary Prevention in Women: Lipids

- Sex-specific data from randomized trials consistently show benefit of treating women with known CHD with statins.
- CARE study shows that women benefit even more from statins in secondary prevention than men.

Percentage of High Risk Women Achieving Optimal Lipid Values



	Baseline (%)	3 Years (%)
LDL-C <100 mg/dl	17	29
HDL-C >50 mg/dl	57	56
TG < 150 mg/dl	57	60
Combined LDL-C, HDL-C, and TG	7	12


Source: Mosca et al. *Circulation*. 2005;111:488-493.

Secondary Prevention in Women: Lipids

- Sex-specific data from randomized trials consistently show benefit of treating women with known CHD with statins.
- CARE study shows that women benefit even more from statins in secondary prevention than men.
- In spite of these data, women are still under-treated

Sources: Walsh et al. *JAMA*. 2004;291:2243-2252. Lewis. *J Am Coll Cardiol*, 1998; 32:140-146

Physician Awareness of AHA Guidelines for Prevention of CVD in Women



Mosca L, et al. Circulation. 2005;111:499-510.

Sex and Gender Differences in CVD: Prevention and Treatment



- Current smoking cessation strategies are less effective in women and data point to a different biology of nicotine addiction in women.
- Women with diabetes have a greater risk of dying of CHD and of developing congestive heart failure compared with men.
- Glycoprotein IIb/IIIa inhibitors, a standard treatment in acute coronary syndromes, show higher bleeding rates and overdosing in women.
- Women with depression are more likely to experience a second heart attack.

Sex and Gender Differences in CVD: Prevention and Treatment



Provision of care:

- Women are more likely to experience delays in primary angioplasty
- Women are less likely to be referred to cardiac rehabilitation and when enrolled are more likely to drop out

Impact of burden of disease:

- Women spend more of their discretionary income on medical care and have higher rates of poverty at both younger and older ages

Inclusion of Women and Minorities in Research

- NIH Revitalization Act of 1993, PL 103-43 established guidelines for inclusion of women and minorities in clinical research
- There is no mandate to report sex-specific data. Few cardiovascular studies report sex-specific results.
 - In a study of 645 cardiovascular trials published in lead medical journals in 2004, only 24% reported sex-specific results
- Overall, sex differences in CVD are inadequately understood, which limits ability to optimize care

Source: Blauwet et al. Mayo Clin Proc. Feb 2007; 82 (2); 166-170.

Racial and Ethnic Disparities



A



B



E



F

Schulman Kevin A, et al. NEJM. 1999;340-624.



Predictors of Referral for Cardiac Catheterization

Factors	Odds Ratio for Catheterization	P Value
---------	-----------------------------------	---------

Race and Sex as Separate Factors

Male	1.0	
Female	0.6 (0.4-0.9)	0.02
White	1.0	
Black	0.6 (0.4-0.9)	0.02


Interaction of Race and Sex

White Male	1.0	
Black Male	1.0 (0.5-2.1)	0.99
White Female	1.0 (0.5-2.1)	>0.99
Black Female	0.4 (0.2-0.7)	0.004

Creating Change

Expand inclusion of women in research and clinical trials

Expand reporting of results by sex, race, and by sex/race



Effectively translate research into clinical care

Use sex-specific data to consider safety of interventions

Sex-stratified quality measures

Improve education and awareness of women, investigators, physicians, and other health care providers

The changing healthcare environment

- Current focus on reforming the healthcare system needs to focus on women as a key group with specialized strategies.
- The Massachusetts experience provides opportunities for expanding women's access to health coverage, including the chance to enhance primary and secondary prevention.

Opportunities for Impact

Expand knowledge and support of prevention programs

- 82% heart disease deaths among women are preventable through controlling risk factors and maintaining a healthy lifestyle
- By controlling these risk factors, women can also reduce their risk of many other chronic illnesses including diabetes, hypertension, chronic obstructive pulmonary disease and cancer

Source: Stampfer et al. NEJM, 2000, Jul 6;343(1):16022

Contact Information

Paula A. Johnson, MD, MPH

- Chief, Division of Women's Health
- Executive Director, Connors Center for Women's Health and Gender Biology

Brigham and Women's Hospital
75 Francis Street, PBB 534
Boston, MA 02115
pajohnson@partners.org



BRIGHAM AND
WOMEN'S HOSPITAL



HARVARD
MEDICAL SCHOOL
TEACHING AFFILIATE

AHA 2007 Guidelines for Preventing CVD in Women



Emphasizes lifetime risk/Includes family hx

- HTN: wt control, increase fresh fruits and vegetables and low-fat dairy
- Smoking: counseling and nicotine replacement
- Physical Activity: 60-90 mins/day to lose or sustain wt loss
- Diet: Saturated fats < 7% percent of cals
omega-3 fatty acid intake-oily fish 2x/wk

AHA 2007 Guidelines for Preventing CVD in Women



- LDL cholesterol: < 70 mg/dl in very high-risk women with heart disease
- AHA does not recommend:
 - HRT and SERMs
 - Antioxidant supplements (vitamins E, C, beta-carotene)
 - Folic acid to prevent CVD
- Low-dose ASA considered in women ≥ 65 yrs if benefits outweigh risks
- Upper dose of ASA for high-risk women is 325 mg

Mosca L, et al. 2007; 115.



References Cited:

- Alexander et al. Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE Initiative. *Circulation*. 2006; 114;1380-1387.
- American Heart Association. Heart Disease and Stroke Statistics–2007 Update.
- Angeja BG, et al. Predictors of door-to-balloon delay in primary angioplasty. *Am J Cardiol*. 2002;89:1156-1161
- Blauwet et al. Low rate of sex-specific result reporting in cardiovascular trials. *Mayo Clin Proc*. Feb 2007; 82 (2); 166-170.
- CDC, National Center for Health Statistics. Health, United States, 2004
- CDC, Office of Women's Health, Leading Causes of Death, Females, US 2003
- Davidson MB. Diabetes Mellitus: Diagnosis and Treatment, 4th ed. Philadelphia: WB Saunders; 1998.



References Cited, cont.

Gould KL. Coronary Artery Stenosis and Reversing Atherosclerosis, 2nd ed. 1999.

King G, et al. Disparities in Smoking Cessation Between African Americans and Whites: 1990-2000. *Am J Public Health*. 2004;94 (11): 1965-1971.

Lewis S, et al. Effect of Pravastatin on Cardiovascular Events in Women after Myocardial Infarction: The Cholesterol and Recurrent Events (CARE) Trial. *JACC*, 1998; 32 (1):140-146

Milner et al. Gender differences in symptom presentation associated with coronary heart disease. *AM J Cardiol*. 1999; 84:396-399

Mosca et al. Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-risk Women in a Managed Care Setting. *Circulation*. 2005;111:488-493.

Mosca L, et al. National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines. *Circulation*. 2005;111:499-510.

References Cited, cont.

Schulman Kevin A, et al. The Effect of Race and Sex on Physicians' Recommendations for Cardiac Catheterization. *NEJM*. 1999; 34: 624.

Shaw, L. The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease: Results From the National Institutes of Health–National Heart, Lung, and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation. *Circulation*. 2006;114;894-904

Stampfer et al. Primary Prevention of Coronary Heart Disease in Women through Diet and Lifestyle. *NEJM*, 2000, Jul 6;343(1):16022

Virmani et al. Lessons From Sudden Coronary Death : A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. *Arterioscler Throm Vasc Biol*. 2000;20:1262-1275.

Walsh et al. Drug Treatment of Hyperlipidemia in Women. *JAMA*. 2004;291:2243-2252.

Witt BJ, et al. Cardiac rehabilitation after myocardial infarction in the community. *J Am Coll Cardiol*. 2004;44 (5):988-96